General Psychiatry

Current Clinical Insights Into Pediatric Anxiety Disorders

09/09/2023

Featuring Manpreet Singh, MD, MS

Featuring Manpreet Singh, MD, MS ...

Manpreet Singh, MD, MS, shares insights from her Psych Congress 2023 session on pediatric anxiety disorders.

Manpreet Singh, MD, MS, shares...

09/09/2023

Psych Congress Network

Christine Moutier, MD, Chief Medical Officer for the American Foundation for Suicide Prevention (AFSP).

News

Transformative ‘Talk Therapy:’ Psych Congress Keynote Considers Medicinal Music

09/07/2023

Brionna Mendoza

The 36th Annual Psych Congress meeting convened on Wednesday, September 6th, in Nashville, Tennessee, with a robust pre-conference program that concluded with the second-ever Eric C. Arauz Memorial Keynote Address.

The 36th Annual Psych Congress...

09/07/2023

Psych Congress Network

News

Psych Congress Partners With AFSP to Enhance Mental Health Education and Community Support

09/05/2023

Meagan Thistle

HMP Global, a health care events and education company, has unveiled an expanded partnership between the annual Psych Congress national meeting and the American Foundation for Suicide Prevention (AFSP).

HMP Global, a health care events...

09/05/2023

Psych Congress Network

Q&As

Demystifying Psychedelic-Assisted Therapies With Andrew Penn, MS, PMHNP

09/20/2022

Andrew Penn, RN, MS, NP, CNS, APRN-BC

Psych Congress Co-Chair Andrew Penn, MS, PMHNP, talks about the therapeutic potential of psychedelic-assisted psychotherapy and the implications for mental healthcare.

Psych Congress Co-Chair Andrew...

09/20/2022

Psych Congress Network

News

Top Executives Share Message of Unification and Urgency With Psych Congress Attendees

09/19/2022

Meagan Thistle

CEO Alliance for Mental Health members presented a message of unification, urgency, and equity.

CEO Alliance for Mental Health...

09/19/2022

Psych Congress Network

News

Zuranolone Eases MDD for Majority of Study Participants, Interim Analysis Shows

09/18/2022

Jolynn Tumolo

An interim analysis of a phase 3, open-label, year-long study evaluating episodic treatment with zuranolone for major depressive disorder found the majority of patients at study exit had minimal or mild depressive symptoms, including those...

An interim analysis of a phase...

09/18/2022

Psych Congress Network